Published 7 days ago • loading... • Updated 6 days ago

Recce soars on phase II skin infection trial results

Summary by Stockhead

A successful phase II clinical trial has taken place, assessing efficacy and safety of R327G in patients with acute bacterial skin and skin structure infections Recce said objectives exceeded with a 93% primary efficacy endpoint achieved for R327G over 14 days of treatment Data confirms approach for registrational phase 3 diabetic foot infections Indonesian trial, where efficacy can now be confirmed earlier in trial Special Report: Recce Pharm…

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

4 Articles

All

Left

Center

Right

Clinical Trials Arena

Recce Pharma exceeds expectations in antibiotic skin gel trial

The Phase II trial saw the antibiotic Recce 327 achieving all primary and secondary endpoints as the company launches a Phase III trial.The post Recce Pharma exceeds expectations in antibiotic skin gel trial appeared first on Clinical Trials Arena.

6 days ago

Read Full Article

pharmafile.com

Recce Pharmaceuticals reports positive phase 2 data for skin infection drug - Pharmafile

Recce Pharmaceuticals have announced positive patient data from its phase 2 clinical trial into RECCE 327 (R327), for the treatment of acute bacterial skin and skin structure infections (ABSSSIs), including diabetic foot infections (DFI). R327, a broad-spectrum antibiotic topical gel, was tested in a phase 2 open-label trial that evaluated its safety, tolerability, efficacy and […] The post Recce Pharmaceuticals reports positive phase 2 data for…

6 days ago

Read Full Article

Stockhead

Recce soars on phase II skin infection trial results

7 days ago

Read Full Article

themarketonline.com.au

Recce finds foot gel to be efficacious in Phase II clinical trial

Recce Pharmaceuticals Ltd (ASX:RCE) has yielded positive data on the effectiveness of its topical gel in treating Acute Bacterial Skin and Skin Structure Infections, including patients with Diabetic Foot Infections, with a primary efficacy endpoint of 93% achieved during its Phase II clinical trial. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and …

7 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year